<DOC>
	<DOCNO>NCT01370772</DOCNO>
	<brief_summary>Phase II , multicenter , randomize trial , explore intensified Rituximab prephase monotherapy standard Fludarabine-Cyclophosphamide-Rituximab FC-R regimen previously untreated symptomatic B-cell chronic lymphocytic leukemia CLL . A Study Goelams GCFLLCMW intergroup</brief_summary>
	<brief_title>Intensified Rituimab Prephase Before FCR Untreated B-CLL</brief_title>
	<detailed_description>Young fit medically B Cell untreated patient Comparison FCR treatment = 6 FCR cycle addition prephase R Dense treatment 6 FCR cycle .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Inclusion criterion : Patient information write informed consent 18 year &lt; Age &lt; 66 an confirm BCLL Matutes score 4 5 Binet stage C Binet stage A B active disease could consider inclusion . For stage A active disease agreement investigator coordinator require . prior treatment except steroid le 1 month ( detail corticoid ) No 17p deletion assess FISH &lt; 10 % positive nuclei Performance status ECOG &lt; 2 CIRS Cumulative Illness Rating Scale &lt; 6 Exclusion criterion : Binet stage A without active disease accord IWCLL 2008 criterion Know HIV seropositivity Hepatitis B C seropositivity unless clearly due vaccination Life expectancy &lt; 6 month Clinically significant autoimmune anemia Active second malignancy currently require treatment ( except basal cell carcinoma situ endometrial carcinoma incidental prostate carcinoma ) and/or le 5 year CR breast cancer Any severe comorbid condition Class III IV heart failure , myocardial infarction within 6 month , unstable angina , ventricular tachyarythmias require ongoing treatment , severe chronic obstructive pulmonary disease hypoxemia , uncontrolled diabetes mellitus , uncontrolled hypertension Concomitant disease require prolong use corticosteroid &gt; 1 month Known hypersensitivity anaphylactic reaction humanize monoclonal antibody study drug According SmPC investigator practice Contraindication use Rituximab Transformation aggressive Bcell malignancy e.g . diffuse large cell lymphoma , Hodgkin lymphoma , prolymphocytic leukaemia Active bacterial , viral fungal infection Abnormal renal function creatinine clearance &lt; 60 ml/min calculate accord Cockcroft Gault formula Total bilirubin , gamma glutamyltransferase transaminase level &gt; 2.5 ULN . Any coexist medical psychological condition would preclude participation require study procedure Patient mental deficiency prevent proper understanding requirement treatment . Pregnant breastfeed woman . Adult lawcontrol Fertile male female patient wish use effective method contraception , 12 month final treatment use purpose study . No afiliate social security</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>B CLL</keyword>
	<keyword>Fist line treatment</keyword>
</DOC>